Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Aug 3, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
45.3%
-23.9% vs 52w high · -6.6% 1mo
Price (last ~year)
Novo Nordisk shares declined 8.8% following the failure of the Phase III ZEUS trial for ziltivekimab, which did not meet its primary endpoint for reducing major adverse cardiovascular events. The company maintains an 83.2% gross margin and 61.6% operating margin, supported by 24.0% year-over-year revenue growth and 67.1% earnings growth as of the most recent quarterly data. With a market capitalization of $208.18 billion, the stock is currently trading at $47.08, representing a 52-week position of 45.3%.
Valuation
- Market cap
- $208.18B
- P/E
- 11.21
- PEG
- 3.16
- P/B
- 6.68
- P/S
- 0.635
- EV/EBITDA
- 8.23
- Beta
- 0.36
- Analyst target
- $47.84
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $47.08
- 1-month
- -6.6%
- 3-month
- +4.9%
- RSI (14)
- 42
- vs SMA200
- +2.3%
- 52-wk position
- 45.3% -23.9% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Bearish Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial · 2026-08-01
- Neutral Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings · 2026-08-01
- Neutral Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings · 2026-07-31
- Bearish Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes · 2026-07-31
- Neutral Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results · 2026-07-31
- Neutral How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results? · 2026-07-30
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)